A randomised comparison of daunorubicin 90mg/m2 vs 60mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.
AffiliationDepartment of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom; firstname.lastname@example.orgDepartment of Haematology, Nottingham University Hospital NHS Trust, Nottingham, United Kingdom;Department of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom;Department of Haematology, University Hospital of Wales, Cardiff, United Kingdom;Department of Haematology, St Bartholomew's Hospital, London, United Kingdom;Department of Haematology, Rigshospitalet, Copenhagen, Denmark;Department of Haematology, Belfast City Hospital, Belfast, United Kingdom;Blackpool Victoria Hospital, Blackpool, United Kingdom;Department of Haematology, Christie Hospital, Manchester, United Kingdom;Department of Haematology, University of Odense, Odense, Denmark;Department of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom;Department of Haematology, Heartlands Hospital, Birmingham, United Kingdom;Department of Haematology, Royal Liverpool University Hospital, Liverpool, United Kingdom
MetadataShow full item record
AbstractModifying induction therapy in AML may improve the remission rate and reduce the risk of relapse thereby improving survival. Escalation of the daunorubicin dose to 90mg/m(2) has shown benefit for some patient subgroups when compared with a dose of 45mg/m(2) and has been recommended as a standard of care. However 60mg/m(2) is widely used and has never been directly compared to 90mg/m(2). As part of the UK NCRI AML17 trial 1206 adults with untreated AML or high risk MDS, mostly under 60 years of age, were randomised to a first induction course of chemotherapy which delivered either 90mg/m(2) or 60mg/m(2) on days 1,3 and 5 combined with cytosine arabinoside. All patients then received a second course which included daunorubicin 50mg/m(2) on days 1,3 and 5. There was no overall difference in complete remission rate (CR) (73% vs 75%, OR1.07 (0.83-1.39), p=0.6) or in any recognised subgroup. The 60 day mortality was increased in the 90mg/m2 arm (10% vs 5% (HR 1.98(1.30-3.02) p=0.001)), which resulted in no difference in overall 2 year survival (59% vs 60%, HR 1.16(0.95-1.43), p=0.15). In exploratory subgroup analysis there was no subgroup which showed significant benefit, although there was a significant interaction by FLT3 ITD mutation. The trial is registered to www.isrctn.com as ISRCTN55675535.
CitationA randomised comparison of daunorubicin 90mg/m2 vs 60mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. 2015: Blood
- Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
- Authors: Freeman SD, Hills RK, Virgo P, Khan N, Couzens S, Dillon R, Gilkes A, Upton L, Nielsen OJ, Cavenagh JD, Jones G, Khwaja A, Cahalin P, Thomas I, Grimwade D, Burnett AK, Russell NH
- Issue date: 2018 May 20
- Daunorubicin 90 mg/m<sup>2</sup> in Acute Myeloid Leukemia Induction: Increased Toxicity in Young Patients.
- Authors: Portugal R, Lyrio R, Loureiro M, Urago K, Bard J, Borchardt A, Garnica M, Nucci M
- Issue date: 2017 Aug
- Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
- Authors: Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ, Kolitz JE, Powell BL, Voorhees P, Wang ES, Blum W, Stone RM, Marcucci G, Bloomfield CD, Moser B, Larson RA
- Issue date: 2013 Mar 1
- Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
- Authors: Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ
- Issue date: 2014 May 22
- Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.
- Authors: Röllig C, Kramer M, Gabrecht M, Hänel M, Herbst R, Kaiser U, Schmitz N, Kullmer J, Fetscher S, Link H, Mantovani-Löffler L, Krümpelmann U, Neuhaus T, Heits F, Einsele H, Ritter B, Bornhäuser M, Schetelig J, Thiede C, Mohr B, Schaich M, Platzbecker U, Schäfer-Eckart K, Krämer A, Berdel WE, Serve H, Ehninger G, Schuler US, Study Alliance Leukemia (SAL).
- Issue date: 2018 Apr 1